News & Opinion
.avif)

Physician Fee Schedule FAQ and Templates
CMS published its FAQ on Bona Fide Service Fee Certifications and ASP Reasonable Assumptions.

MDRP 2025 Wrap-up
Salient topics and key takeaways from the MDRP 2025 conference.

MFN Executive Order Update
Interpretation of the evolving demands from the administration, and recommendations for manufacturers.

Inc. 5000 Fastest-Growing Company
We've been named one of Inc. 5000 fastest-growing companies.

340B Rebate Model Pilot Program
The pilot includes 10 drugs and is soliciting manufacturer comments.

The New Medicare P Code Process
Starting in 2026, manufacturers can gain a P Code on a quarterly basis.

Most-Favored-Nation Executive Order
Proposed actions manufacturers can take in light of the MFN Executive Order.

Woven Data Announces a New Analytical Capability to Answer What-if Questions
Cloning the entire analytical environment to explore potential changes.

Insights from the Q1 Medicare MDP Rebate Processing Cycle
A recap of emerging Medicare MDP trends.

Tariffs and the Pharma Industry
Scenario planning for tariffs on pharmaceuticals.

VA FSS: US-Made Products
New "Made in America" policies and potential actions required to mark products as "US-Made."

2025 GP Calendar
Add the 2025 GP Calendar to your Outlook or Google Calendar.

Medicaid Rebates and the AMP Cap Removal – Building Your Internal Analytics
Stay on top of changes like the AMP cap removal.

2025 Public Law
Key dates and documents for the VA 2025 Public Law.

Medicare Updates & Notes for Manufacturers
Key dates and requirements from the recent CMS Medicare implementation memos.

IRA Negotiations Round 1
Thoughts on the first round of the Inflation Reduction Act drug price negotiations.

2025 Annual Public Law Preparation
VA has begun preparations for the 2025 Public Law. Here is what you need to get started.

Reimbursement Rules with Zero or Negative ASP
CMS rules published as part of the Physician Fee Schedule for 2025.

Authorized Generics
What the Authorized Generics are, and how they are treated in Government Pricing calculations and commercially.

The impacts of PBMs according to the FTC
Observations from the FTC report on the impact of PBMs on drug pricing.
Talk to an Expert
Get Started%20(1).avif)
.avif)